ACA Muller ADAG Pharma AG secures contract for Pharmaceutical products - conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient Omalizumab, ATC R03DX05 for the period 01082024 - 31072025 (plus extension option 1x12 months)

Germany, Sept. 3 -- Germany based ACA Muller ADAG Pharma AG has secured contract from DAK-Gesundheit for Pharmaceutical products - conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient Omalizumab, ATC R03DX05 for the period 01082024 - 31072025 (plus extension option 1x12 months) . The value of the contract is not disclosed .

Published by HT Digital Content Services with permission from Pivotal Sources....